The positive results from the Phase 3 trial of reproxalap ophthalmic solution indicate that the drug is effective in treating allergic conjunctivitis. This achievement of statistical significance for the primary endpoint and all secondary endpoints is a strong indicator of the drug's potential success in the market. As a result, investors are likely to view this news positively, leading to an increase in demand for ALDX shares and driving the stock price up by 11%.